Cara Therapeutics, VFMCRP get EC approval for Kapruvia for pruritus
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) said that Kapruvia (difelikefalin) has secured approval from the European Commission (EC) for the treatment of moderate-to-severe pruritus linked to chronic kidney disease (CKD) in adult hemodialysis patients. The marketing authorization enables Kapruvia to be used in all member states of the European Union along […]